NCT02109874View on ClinicalTrials.gov

A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

September 30, 2012

Conditions
Tuberculosis
Interventions
BIOLOGICAL

AERAS-404 (mcg H4/nmol IC31)

Dose escalation

BIOLOGICAL

Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl

Trial Locations (1)

Unknown

South African Tuberculosis Vaccine Institute; Brewelskloof Hospital, Worcester

Sponsors

Lead Sponsor

Aeras
All Listed Sponsors
collaborator

Statens Serum Institut

OTHER

lead

Aeras

OTHER

NCT02109874 - A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404) | Biotech Hunter | Biotech Hunter